Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials

被引:379
作者
Keeley, EC [1 ]
Boura, JA
Grines, CL
机构
[1] Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA
[2] William Beaumont Hosp, Royal Oak, MI 48072 USA
关键词
D O I
10.1016/S0140-6736(06)68148-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Facilitated percutaneons coronary intervention for ST-segment-elevation myocardial infarction (STEMI) is defined as the use of pharmacological substances before a planned immediate intervention, to improve coronary patency. We undertook a meta-analysis of randomised controlled trials (published and unpublished) to compare facilitated and primary percutaneous coronary intervention. Methods We identified 17 trials of patients with STEMI assigned to facilitated (n=2237) or primary (n=2267) percutaneous coronary intervention. We identified short-term outcomes (up to 42 days) of death, stroke, non-fatal reinfarction, urgent target vessel revascularisation, and major bleeding. Grade 3 flow rates for prethrombolysis and post-thrombolysis in myocardial infarction (TIMI) were also analysed. Findings The facilitated approach resulted in a greater than two-fold increase in the number of patients with initial TIMI grade 3 flow, compared with the primary approach (832 patients [37%] vs 342 [15%], odds ratio 3.18, 95% CI 2.22-4.55); however, final rates did not differ (1706 [89%] vs 1803 [88%]; 1.19, 0.86-1.64). Significantly more patients assigned to the facilitated approach than those assigned to the primary approach died (106 [5%] vs 78 [3%]; 1.38, 1.01-1.87), had higher non-fatal reinfarction rates (74 [3%] vs 41 [2%]; 1.71, 1.16-2.51), and had higher urgent target vessel revascularisation rates (66 [4%] vs 21 [1%]; 2.39, 1.23-4.66); the increased rates of adverse events seen with the facilitated approach were mainly seen in thrombolytic-therapy-based regimens. Facilitated intervention was associated with higher rates of major bleeding than primary intervention (159 [7%] vs 108 [5%]; 1.51, 1.10-2.08). Haemorrhagic stroke and total stroke rates were higher in thrombolytic-therapy-containing facilitated regimens than in primary intervention (haemorrhagic stroke 15 [0.7%] vs two [0.1%], p=0.0014; total stroke 24 [1.1%] vs six [0.3%], p=0.0008). Interpretation Facilitated percutaneous coronary intervention offers no benefit over primary percutaneous coronary intervention in STEMI treatment and should not be used outside the context of randomised controlled trials. Furthermore, facilitated interventions with thrombolytic-based regimens should be avoided.
引用
收藏
页码:579 / 588
页数:10
相关论文
共 28 条
  • [1] Task force 1: The ACCF and AHA codes of conduct in human subjects research
    Adams, RJ
    Antman, EM
    Kavey, REW
    [J]. CIRCULATION, 2004, 110 (16) : 2512 - 2516
  • [2] Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide, monotherapy in acute Myocardial Infarction (ADVANCE MI) trial
    Adgey, J
    Ardissino, D
    Armstrong, P
    Berger, P
    Betriu, A
    Beyar, R
    Bode, C
    Braunwald, E
    Brindis, R
    Brogan, G
    Buller, C
    Califf, R
    Casterella, P
    Gibler, WB
    Giugliano, R
    Goldstein, P
    Granger, C
    Guetta, V
    Harrington, R
    Herrmann, H
    Hochman, J
    Hoekstra, J
    Kleiman, N
    Labinaz, M
    Langer, A
    Montalescot, G
    Ohman, EM
    O'Neill, W
    Pollack, C
    Roe, M
    Satler, L
    Schweiger, M
    Simoons, M
    Steg, G
    Tanguay, JF
    Van de Werf, F
    Wallentin, L
    Zeymer, U
    [J]. AMERICAN HEART JOURNAL, 2005, 150 (01) : 116 - 122
  • [3] Prehospital versus periprocedural administration of abciximab in STEMI:: early and late results from the randomised REOMOBILE-study
    Arntz, HR
    Schröder, JF
    Peis, K
    Schwimmbeck, P
    Witzenbichler, B
    Schultheiss, HP
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 : 268 - 268
  • [4] BELLANDI F, 2005, INT J CARDIOL, DOI DOI 10.1016/IJCARD.2005.04.025
  • [5] Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction
    Brodie, BR
    Stuckey, TD
    Hansen, C
    Muncy, D
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (01) : 13 - 18
  • [6] Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction
    Cutlip, DE
    Ricciardi, MJ
    Ling, FS
    Carrozza, JP
    Dua, V
    Garringer, J
    Giri, S
    Caputo, RP
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (08) : 977 - 980
  • [7] Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty
    De Luca, G
    Ernst, N
    Zijlstra, F
    van't Hof, AWJ
    Hoorntje, JCA
    Dambrink, JHE
    Gosslink, ATM
    de Boer, MJ
    Suryapranata, H
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (08) : 1363 - 1367
  • [8] Fernández-Avilés F, 2004, EUR HEART J, V25, P33
  • [9] Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI Frame Count:: results of the ERAMI trial
    Gabriel, HM
    Oliveira, J
    da Silva, PC
    da Costa, JM
    da Cunha, JAC
    França, C
    Vagueiro, MC
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 : 543 - 543
  • [10] Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction - Is the slope of the curve the shape of the future?
    Gersh, BJ
    Stone, GW
    White, HD
    Holmes, DR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (08): : 979 - 986